Corcept (CORT) Shares Rise 20% in Three Months: Here's Why

Shares of Corcept Therapeutics Incorporated (CORT) have rallied 20% in the past three months against the industry's decline of 4.9%. The GRACE study consists of two parts — the open-label portion and the randomized withdrawal phase. Last month, CORT announced that the GRACE study met the primary endpoint in the randomized withdrawal phase. Data from the same showed that patients who were treated with relacorilant experienced loss of blood pressure control, the study's primary endpoint, versus placebo. Notab ...